LEGISLATIVE BUDGET BOARD Austin, Texas FISCAL NOTE, 88TH LEGISLATIVE REGULAR SESSION March 16, 2023 TO: Honorable Lois W. Kolkhorst, Chair, Senate Committee on Health & Human Services FROM: Jerry McGinty, Director, Legislative Budget Board IN RE: SB241 by Perry (Relating to written notification provided by drug manufacturers regarding the cause of generic or biosimilar insulin prescription drug unavailability), Committee Report 1st House, Substituted No significant fiscal implication to the State is anticipated. It is assumed that any costs associated with the bill could be absorbed using existing resources. Local Government ImpactNo fiscal implication to units of local government is anticipated. Source Agencies: b > td > 529 Health and Human Services Commission, 537 State Health Services, Department of LBB Staff: b > td > JMc, NPe, ER, CST LEGISLATIVE BUDGET BOARD Austin, Texas FISCAL NOTE, 88TH LEGISLATIVE REGULAR SESSION March 16, 2023 TO: Honorable Lois W. Kolkhorst, Chair, Senate Committee on Health & Human Services FROM: Jerry McGinty, Director, Legislative Budget Board IN RE: SB241 by Perry (Relating to written notification provided by drug manufacturers regarding the cause of generic or biosimilar insulin prescription drug unavailability), Committee Report 1st House, Substituted TO: Honorable Lois W. Kolkhorst, Chair, Senate Committee on Health & Human Services FROM: Jerry McGinty, Director, Legislative Budget Board IN RE: SB241 by Perry (Relating to written notification provided by drug manufacturers regarding the cause of generic or biosimilar insulin prescription drug unavailability), Committee Report 1st House, Substituted Honorable Lois W. Kolkhorst, Chair, Senate Committee on Health & Human Services Honorable Lois W. Kolkhorst, Chair, Senate Committee on Health & Human Services Jerry McGinty, Director, Legislative Budget Board Jerry McGinty, Director, Legislative Budget Board SB241 by Perry (Relating to written notification provided by drug manufacturers regarding the cause of generic or biosimilar insulin prescription drug unavailability), Committee Report 1st House, Substituted SB241 by Perry (Relating to written notification provided by drug manufacturers regarding the cause of generic or biosimilar insulin prescription drug unavailability), Committee Report 1st House, Substituted No significant fiscal implication to the State is anticipated. No significant fiscal implication to the State is anticipated. It is assumed that any costs associated with the bill could be absorbed using existing resources. Local Government Impact No fiscal implication to units of local government is anticipated. Source Agencies: b > td > 529 Health and Human Services Commission, 537 State Health Services, Department of 529 Health and Human Services Commission, 537 State Health Services, Department of LBB Staff: b > td > JMc, NPe, ER, CST JMc, NPe, ER, CST